Search results
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
For active lupus nephritis, GC, mycophenolate or low- dose intravenous CYC are recommended as anchor drugs, and add- on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus ery-thematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
Bullous systemic lupus erythematosus (BSLE) is an autoantibody-mediated vesiculobullous disease in patients with SLE. Autoimmunity in BSLE is characterized by the presence of circulating anti-type VII collagen antibodies.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [ 1 – 3 ].
The purpose of this document is to present and discuss the rationale of the recommendations on the general management of SLE, specifically, clinical follow-up, general therapeutic approach, healthy lifestyles, photoprotection, and training programs for patients.
